Charles Jensen
Jensen’s expertise in the field spans 20 years, 15 of which were served at Eli Lilly and Co., where he was most recently senior study director for drug development services for In Vitro Technologies.
AMRI hope Jensen’s appointment will support their drug discovery team as it becomes more involved in fully integrated discovery biology and chemistry programs.
Bruce Sargent, senior VP of drug discovery said: “At AMRI, we consider early ADMET profiling and pharmacokinetic analysis to be crucial components of the drug discovery process, and we are excited to have Dr. Jensen join us with his substantial experience in these fields.”